Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences

Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming
                             Investor Conferences

PR Newswire

MOUNTAIN VIEW, Calif., Feb. 25, 2013

MOUNTAIN VIEW, Calif., Feb. 25, 2013 /PRNewswire/ -- Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast
live at three upcoming investor conferences. A live webcast of each
presentation may be accessed from the Investor Relations section of the Alexza
Pharmaceuticals website at www.alexza.com. The conferences and presentation
times include:

  oCowen & Company 33^rd Annual Health Care Conference in Boston, MA on
    Tuesday, March 5, 2013 at 11:20 am ET
  o25^th Annual ROTH Conference in Dana Point, CA on Monday, March 18, 2013
    at 5:30 pm ET
  oFuture Leaders in the Biotech Industry Conference in New York, NY on
    Friday, April 5, 2013 at 10:30 am ET

A replay of each webcast will be available approximately 24 hours following
the completion of the respective presentation and will be available for 14
days following the each presentation, on the Investor Relations section of the
company's website.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler that is designed to deliver a drug aerosol to the deep
lung, providing rapid systemic delivery and therapeutic onset with ease and
convenience for patients.

ADASUVE^® (Staccato loxapine) is Alexza's first approved product, which was
approved by the U.S. Food and Drug Administration in December 2012 and by the
European Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A.
is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia
and the Commonwealth of Independent States countries. The commercial launch
of ADASUVE is planned for the third quarter 2013 in the U.S. and Europe.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. For more
information about ADASUVE, please visit www.adasuve.com.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,
Inc.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties. Any statement describing the
Company's expectations or beliefs is a forward-looking statement, as defined
in the Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of developing
and commercializing drugs, including the ability for Alexza and Ferrer to
effectively and profitably commercialize ADASUVE, the adequacy of the
Company's capital to support the Company's operations, and the Company's
ability to raise additional funds and the potential terms of such potential
financings. The Company's forward-looking statements also involve assumptions
that, if they prove incorrect, would cause its results to differ materially
from those expressed or implied by such forward-looking statements. These and
other risks concerning Alexza's business are described in additional detail in
the Company's Annual Report on Form 10-K for the year ended December 31, 2011
and the Company's other Periodic and Current Reports filed with the Securities
and Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Website: http://www.alexza.com
Contact: BCC Partners, Karen L. Bergman and Michelle Corral, +1-650-575-1509
or +1-415-794-8662, kbergman@bccpartners.com or mcorral@bccpartners.com
 
Press spacebar to pause and continue. Press esc to stop.